One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model

Karen Gooch, Trevor R.F. Smith, Francisco Javier Salguero Bodes, Susan Fotheringham, Robert Watson, Michael Dennis, Alastair Handley, Holly Humphries, Stephanie Longet, Thomas Tipton, Charlotte Sarfas, Laura Sibley, Gillian Slack, Emma Rayner, Kathryn Ryan, Katherine Schultheis, Stephanie J. Ramos, Andrew White, Susan Charlton, Sally SharpeFergus Gleeson, Laurent M. Humeau, Yper Hall, Kate E. Broderick*, Miles Carroll

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Safe and effective vaccines will provide essential medical countermeasures to tackle the COVID-19 pandemic. Here, we assessed the safety, immunogenicity and efficacy of the intradermal delivery of INO4800, a synthetic DNA vaccine candidate encoding the SARS-CoV-2 spike protein in the rhesus macaque model. Single and 2 dose vaccination regimens were evaluated. Vaccination induced both binding and neutralizing antibodies, along with IFN-gamma-producing T cells against SARS-CoV-2. Upon administration of a high viral dose (5 x 10(6) pfu) via the intranasal and intratracheal routes we observed significantly reduced virus load in the lung and throat, in the vaccinated animals compared to controls. 2 doses of INO-4800 was associated with more robust vaccine-induced immune responses and improved viral protection. Importantly, histopathological examination of lung tissue provided no indication of vaccine-enhanced disease following SARS-CoV-2 challenge in INO-4800 immunized animals. This vaccine candidate is currently under clinical evaluation as a 2 dose regimen. 

Original languageEnglish
Pages (from-to)4885-4894
JournalVaccine
Volume39
Issue number34
Early online date23 Jun 2021
DOIs
Publication statusPublished - 9 Aug 2021

Bibliographical note

Funding Information: The studies described in this manuscript were funded by a grant from the Coalition for Epidemic Preparedness Innovations (CEPI). The authors would like to thank Amy Shurtleff for her expert advice throughout this study. We would also like to thank the David Weiner laboratory at the Wistar Institute for their valuable support of the INO-4800 vaccine program. We would like to thank Maria Yang and the Inovio plasmid production team for generating the DNA constructs and formulation, Matthew Coultas and the Inovio logistics team for overseeing shipment of the biologics and drug delivery equipment. Thank you to Lauren Allen, Emily Brunt, Breeze E Cavell, Rebecca Cobb, Konstantinos Gkolfinos, Kerry J Godwin, Jade Gouriet, Richard Hesp, Charlotte Hind, Catherine M. K. Ho, Stephanie Leung, Jennifer Logue, Vanessa Lucas, Adam Mabbutt, Alexandra Morrison, Jemma Patterson, Elizabeth J. Penn, Stephen Thomas, Nadina Wand for assistance with sample processing and analysis, Laura Hunter and Chelsea Kennard for histology analysis and Debbie Harris, Nathan Wiblin and all Biological Investigations Group staff for animal husbandry and assistance with in vivo procedures.

Open Access: This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Publisher Copyright: Crown Copyright © 2021 Published by Elsevier Ltd.

Citation: Karen E. Gooch, Trevor R.F. Smith, Francisco J. Salguero, Susan A. Fotheringham, Robert J. Watson, Mike J. Dennis, Alastair Handley, Holly E. Humphries, Stephanie Longet, Tom Tipton, Charlotte Sarfas, Laura Sibley, Gillian S. Slack, Emma Rayner, Kathryn A. Ryan, Katherine Schultheis, Stephanie J. Ramos, Andrew White, Sue Charlton, Sally A. Sharpe, Fergus Gleeson, Laurent M. Humeau, Yper Hall, Kate E. Broderick, Miles W. Carroll, One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model, Vaccine, Volume 39, Issue 34, 2021, Pages 4885-4894, ISSN 0264-410X.

DOI: https://doi.org/10.1016/j.vaccine.2021.06.057.

Keywords

  • COVID-19
  • DNA vaccine
  • Nonhuman Primate Virus Challenge
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model'. Together they form a unique fingerprint.

Cite this